vs
Side-by-side financial comparison of Insulet Corporation (PODD) and SEALED AIR CORP (SEE). Click either name above to swap in a different company.
SEALED AIR CORP is the larger business by last-quarter revenue ($1.4B vs $783.7M, roughly 1.8× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 3.1%, a 9.8% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 2.6%). SEALED AIR CORP produced more free cash flow last quarter ($257.7M vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 2.7%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Sealed Air Corporation is a global provider of innovative packaging and protective solutions. Its core offerings include cushioning materials, food safety and preservation packaging, and sustainable waste-reducing packaging systems, serving retail, e-commerce, food and beverage, and industrial manufacturing markets worldwide.
PODD vs SEE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $1.4B |
| Net Profit | $101.6M | $43.8M |
| Gross Margin | 72.6% | 28.6% |
| Operating Margin | 18.7% | 11.4% |
| Net Margin | 13.0% | 3.1% |
| Revenue YoY | 31.2% | 2.6% |
| Net Profit YoY | 0.9% | 700.0% |
| EPS (diluted) | $1.42 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $783.7M | $1.4B | ||
| Q3 25 | $706.3M | $1.3B | ||
| Q2 25 | $649.1M | $1.3B | ||
| Q1 25 | $569.0M | $1.3B | ||
| Q4 24 | $597.5M | $1.4B | ||
| Q3 24 | $543.9M | $1.3B | ||
| Q2 24 | $488.5M | $1.3B | ||
| Q1 24 | $441.7M | $1.3B |
| Q4 25 | $101.6M | $43.8M | ||
| Q3 25 | $87.6M | $255.1M | ||
| Q2 25 | $22.5M | $93.1M | ||
| Q1 25 | $35.4M | $113.5M | ||
| Q4 24 | $100.7M | $-7.3M | ||
| Q3 24 | $77.5M | $91.7M | ||
| Q2 24 | $188.6M | $98.3M | ||
| Q1 24 | $51.5M | $82.0M |
| Q4 25 | 72.6% | 28.6% | ||
| Q3 25 | 72.2% | 29.8% | ||
| Q2 25 | 69.7% | 30.7% | ||
| Q1 25 | 71.9% | 30.9% | ||
| Q4 24 | 72.1% | 30.0% | ||
| Q3 24 | 69.3% | 30.1% | ||
| Q2 24 | 67.7% | 31.2% | ||
| Q1 24 | 69.5% | 30.3% |
| Q4 25 | 18.7% | 11.4% | ||
| Q3 25 | 16.7% | 13.8% | ||
| Q2 25 | 18.7% | 15.0% | ||
| Q1 25 | 15.6% | 14.5% | ||
| Q4 24 | 18.3% | 11.7% | ||
| Q3 24 | 16.2% | 13.9% | ||
| Q2 24 | 11.2% | 15.4% | ||
| Q1 24 | 12.9% | 14.0% |
| Q4 25 | 13.0% | 3.1% | ||
| Q3 25 | 12.4% | 19.0% | ||
| Q2 25 | 3.5% | 7.0% | ||
| Q1 25 | 6.2% | 9.0% | ||
| Q4 24 | 16.9% | -0.5% | ||
| Q3 24 | 14.2% | 6.9% | ||
| Q2 24 | 38.6% | 7.4% | ||
| Q1 24 | 11.7% | 6.2% |
| Q4 25 | $1.42 | $0.30 | ||
| Q3 25 | $1.24 | $1.73 | ||
| Q2 25 | $0.32 | $0.63 | ||
| Q1 25 | $0.50 | $0.77 | ||
| Q4 24 | $1.38 | $-0.05 | ||
| Q3 24 | $1.08 | $0.63 | ||
| Q2 24 | $2.59 | $0.67 | ||
| Q1 24 | $0.73 | $0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $344.0M |
| Total DebtLower is stronger | $930.8M | $3.3B |
| Stockholders' EquityBook value | $1.5B | $1.2B |
| Total Assets | $3.2B | $7.0B |
| Debt / EquityLower = less leverage | 0.61× | 2.65× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $344.0M | ||
| Q3 25 | — | $282.5M | ||
| Q2 25 | — | $354.4M | ||
| Q1 25 | — | $335.2M | ||
| Q4 24 | — | $371.8M | ||
| Q3 24 | — | $386.0M | ||
| Q2 24 | — | $388.6M | ||
| Q1 24 | — | $352.8M |
| Q4 25 | $930.8M | $3.3B | ||
| Q3 25 | $934.9M | $4.0B | ||
| Q2 25 | $939.0M | $4.0B | ||
| Q1 25 | $1.6B | $4.2B | ||
| Q4 24 | $1.3B | $4.2B | ||
| Q3 24 | $1.4B | $4.3B | ||
| Q2 24 | $1.4B | $4.4B | ||
| Q1 24 | $1.4B | $4.5B |
| Q4 25 | $1.5B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.5B | $953.1M | ||
| Q1 25 | $1.3B | $797.9M | ||
| Q4 24 | $1.2B | $624.5M | ||
| Q3 24 | $1.1B | $771.2M | ||
| Q2 24 | $998.4M | $650.1M | ||
| Q1 24 | $790.7M | $598.3M |
| Q4 25 | $3.2B | $7.0B | ||
| Q3 25 | $3.0B | $7.1B | ||
| Q2 25 | $3.5B | $7.2B | ||
| Q1 25 | $3.5B | $7.0B | ||
| Q4 24 | $3.1B | $7.0B | ||
| Q3 24 | $3.0B | $7.3B | ||
| Q2 24 | $2.9B | $7.3B | ||
| Q1 24 | $2.6B | $7.2B |
| Q4 25 | 0.61× | 2.65× | ||
| Q3 25 | 0.68× | 3.34× | ||
| Q2 25 | 0.64× | 4.18× | ||
| Q1 25 | 1.21× | 5.26× | ||
| Q4 24 | 1.07× | 6.72× | ||
| Q3 24 | 1.21× | 5.62× | ||
| Q2 24 | 1.36× | 6.81× | ||
| Q1 24 | 1.72× | 7.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | $293.6M |
| Free Cash FlowOCF − Capex | $48.2M | $257.7M |
| FCF MarginFCF / Revenue | 6.2% | 18.5% |
| Capex IntensityCapex / Revenue | 17.2% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.80× | 6.70× |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | $458.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.3M | $293.6M | ||
| Q3 25 | $125.7M | $165.9M | ||
| Q2 25 | $196.5M | $136.6M | ||
| Q1 25 | $63.8M | $31.9M | ||
| Q4 24 | $147.7M | $244.2M | ||
| Q3 24 | $98.5M | $170.5M | ||
| Q2 24 | $96.5M | $188.2M | ||
| Q1 24 | $87.6M | $125.1M |
| Q4 25 | $48.2M | $257.7M | ||
| Q3 25 | $100.1M | $119.6M | ||
| Q2 25 | $177.9M | $93.2M | ||
| Q1 25 | $51.5M | $-12.0M | ||
| Q4 24 | $94.1M | $185.1M | ||
| Q3 24 | $71.8M | $115.2M | ||
| Q2 24 | $74.0M | $129.5M | ||
| Q1 24 | $65.5M | $78.0M |
| Q4 25 | 6.2% | 18.5% | ||
| Q3 25 | 14.2% | 8.9% | ||
| Q2 25 | 27.4% | 7.0% | ||
| Q1 25 | 9.1% | -0.9% | ||
| Q4 24 | 15.7% | 13.6% | ||
| Q3 24 | 13.2% | 8.6% | ||
| Q2 24 | 15.1% | 9.7% | ||
| Q1 24 | 14.8% | 5.9% |
| Q4 25 | 17.2% | 2.6% | ||
| Q3 25 | 3.6% | 3.4% | ||
| Q2 25 | 2.9% | 3.3% | ||
| Q1 25 | 2.2% | 3.5% | ||
| Q4 24 | 9.0% | 4.4% | ||
| Q3 24 | 4.9% | 4.1% | ||
| Q2 24 | 4.6% | 4.4% | ||
| Q1 24 | 5.0% | 3.6% |
| Q4 25 | 1.80× | 6.70× | ||
| Q3 25 | 1.43× | 0.65× | ||
| Q2 25 | 8.73× | 1.47× | ||
| Q1 25 | 1.80× | 0.28× | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.27× | 1.86× | ||
| Q2 24 | 0.51× | 1.91× | ||
| Q1 24 | 1.70× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
SEE
| Protective Segment | $1.1B | 78% |
| Other | $292.0M | 21% |
| Pension Plans Defined Benefit | $7.9M | 1% |
